| Description |
GSK'872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM.
|
| Related Catalog |
|
| Target |
RIPK3[1]
|
| In Vitro |
GSK'872 blocks necroptosis in mouse cells. RIP3i GSK'872 inhibits TLR3- or DAI-induced death, two RIP1-independent pathways of necroptosis[1]. Pretreatment with GSK'872 (GSK-872) confers significant protection to primary hepatocytes. However, RIPK1 inhibition (by Nec1) does not impart any protection to primary hepatocytes[2].
|
| Cell Assay |
Cell viability is estimated by Trypan blue exclusion and MTT assay. Treatment of inhibitors [N-acetyl Cysteine (NAC), butylated hydroxyanisole (BHA), IM54, Bay11-7082, Z-VAD-FMK, caspase-8 inhibitor, GSK'872 (200 nM) and necrostatin-1 (Nec-1)] is given for 4 h before Deltamethrin (DLM) treatment[2].
|
| References |
[1]. Mandal P, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014 Nov 20;56(4):481-95. [2]. Arora D, et al. Deltamethrin induced RIPK3-mediated caspase-independent non-apoptotic cell death in rat primary hepatocytes. Biochem Biophys Res Commun. 2016 Oct 14;479(2):217-223.
|
